Amundi’s Amicus Therapeutics FOLD Stock Holding History

Amundi’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$371K	Buy	+25,627	New	+$367K	﹤0.01%	1666
2022 Q4	–	Sell	-12,280	Closed	-$133K	–	1932
2022 Q3	$133K	Hold	12,280	–	–	﹤0.01%	1514
2022 Q2	$135K	Hold	12,280	–	–	﹤0.01%	1405
2022 Q1	$111K	Hold	12,280	–	–	﹤0.01%	1457
2021 Q4	$122K	Sell	12,280 -2,272	-16%	-$25.3K	﹤0.01%	1543
2021 Q3	$139K	Sell	14,552 -2,203	-13%	-$22.5K	﹤0.01%	1484
2021 Q2	$162K	Buy	+16,755	New	+$164K	﹤0.01%	1420

Other funds holding FOLD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Amundi's FOLD Position: Q1 2026 in Review

Amundi opened a new position in Amicus Therapeutics (FOLD) in Q1 2026: 25,627 shares worth $371K. The stake represents ﹤0.01% of the portfolio and ranks #1666 among its holdings. This is a return to the name: Amundi previously reported a position in FOLD as recently as Q3 2022.

Amundi first reported a position in FOLD in Q2 2021 and has held it in 7 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Amundi held 25,627 shares of Amicus Therapeutics worth $371K as of Q1 2026.
Amicus Therapeutics was a new Amundi position in Q1 2026.
Amicus Therapeutics made up ﹤0.01% of Amundi's portfolio in Q1 2026, its #1666 holding.
Amundi first reported a position in Amicus Therapeutics in Q2 2021 and has held it in 7 quarters since.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Amundi's 13F filing for Q1 2026, filed 18 May 2026.